Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 959-962

  Reilley, Sandra ^a   Wenzel, Eric ^b   Reynolds, Laurie ^c   Bennett, Beth ^b,c   Patti, Joseph M ^b   Hetherington, Seth ^b  

^a Northwest Kinetics   (United States)

^b ICON Development Solutions   (United States)

^c Inhibitex Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUREXIS; MONOCLONAL ANTIBODY; TEFIBAZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL GRAFT; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG SCREENING; ERYTHEMA; FEMALE; GASTROINTESTINAL REFLUX; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NEUTROPENIA; NORMAL HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TISSUE DISTRIBUTION;

ADHESINS, BACTERIAL; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; FEMALE; HUMANS; MALE; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS;

EID: 14744277458     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.959-962.2005     Document Type: Article

References (15)

1. Chuard, C., P. Vaudaux, F. A. Waldvogel, and D. P. Lew. 1993. Susceptibility of Staphylococcus aureus growing on fibronectin-coated surfaces to bactericidal antibiotics. Antimicrob. Agents Chemother. 37:625-632.
2. Foster, T. J., and M. Hook. 1998. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 6:484-488.
3. Josefsson, E., O. Hartford, L. O'Brien, J. M. Patti, and T. Foster. 2001. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J. Infect. Dis. 184:1572-1580.
4. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339:520-532.
5. McDevitt, D., P. Francois, P. Vaudaux, and T. J. Foster. 1994. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol. Microbiol. 11:237-248.
6. McDevitt, D., P. Vaudaux, and T. J. Foster. 1992. Genetic evidence that bound coagulase of Staphylococcus aureus is not clumping factor. Infect. Immun. 60:1514-1523.
7. Meissner, H. C., J. R. Groothuis, W. J. Rodriguez, R. C. Welliver, G. Hogg, P. H. Gray, R. Loh, E. A. F. Simoes, P. Sly, A. K. Miller, A. I. Nichols, D. K. Jorkasky, D. E. Everitt, and K. A. Thompson. 1999. Safety and pharmacokinetics of an intramuscular antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. Antimicrob. Agents Chemother. 45:1183-1188.
8. Moreillon, P., J. M. Entenza, P. Francioli, D. McDevitt, T. J. Foster, P. Francois, and P. Vaudaux. 1995. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect. Immun. 63:4738-4743.
9. Patti, J. M., H. Jonsson, B. Guss, L. M. Switalski, K. Wiberg, M. Lindberg, and M. Hook. 1992. Molecular characterization and expression of a gene encoding a Staphylococcus aureus collagen adhesin. J. Biol. Chem. 267:4766-4772.
10. Pillai, S. K., G. Sakoulas, C. Wennersten, G. M. Eliopoulos, R. C. Moellering, Jr., M. J. Ferraro, and H. S. Gold. 2002. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J. Infect. Dis. 186:1603-1607.
11. Plosker, P. L., and D. P. Figgit. 2003. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63:803-843.
12. Que, Y.-A., J.-A. Haefliger, P. Francioli, and P. Moreillon. 2000. Expression of Staphylococcus aureus clumping factor A in Lactococcus lactis subsp. cremoris using a new shuttle vector. Infect. Immun. 68:3516-3522.
13. Stutzmann Meier, P., J. M. Entenza, P. Vaudaux, P. Francioli, M. P. Glauser, and P. Moreillon. 2001. Study of Staphylococcus aureus pathogenic genes by transfer and expression in the less virulent organism Streptococcus gordonii. Infect. Immun. 69:657-664.
14. Subramanian, K. N., L. E. Weisman, T. Rhodes, R. Ariagno, P. J. Sanchez, J. Steichen, L. B. Givner, T. L. Jennings, F. H. Top, Jr., D. Carlin, E. Connor, and the MEDI-493 Study Group. 1998. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. 17:110-115.
15. Wilson, P., J. A. Andrews, R. Charlesworth, R. Walesby, M. Singer, D. J. Farrell, and M. Robbins. 2003. Linezolid resistance in clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 51:186-188.